Monterail adds MAE Group to HealthTech partner network

Monterail has added MAE Group to its HealthTech Universe, giving healthcare product teams access to regulatory, clinical, and commercialization support alongside software development. The move is meant to reduce redesigns, speed FDA and other approvals, and help products reach market with less friction.

Why it matters: - HealthTech products often stall when regulatory and commercialization issues surface after development is already underway. - The partnership gives Monterail clients a single path from product concept to regulatory clearance and market entry. - The addition is aimed at reducing redesigns, delays, and deadline pressure for companies building regulated healthcare software and devices.

What happened: - Monterail announced a partnership with MAE Group, a global medtech advisory and commercialization firm. - MAE Group is now part of Monterail HealthTech Universe, a partner network covering regulatory, clinical, hardware, legal, and market-access expertise. - Monterail said the network is designed for HealthTech clients that need development support plus specialized guidance across the product journey.

The details: - Monterail has delivered more than 900 products globally, including 75+ healthcare products and 15+ regulated devices. - Monterail counts clients such as DocPlanner, Merck, Elvie, and Eargo. - MAE Group was founded in 2013 and is led by a CEO with more than 20 years in medical devices and commercialization. - MAE Group reports a 100% regulatory success rate across the approvals it has managed. - MAE Group has guided products through FDA, ISO, and CE pathways for companies ranging from startups to large pharmaceutical firms. - Monterail said the HealthTech Universe was built so clients do not have to assemble regulatory and commercialization expertise piece by piece under deadline pressure. - Monterail said its HealthTech work combines product strategy, UX, and software engineering for web, mobile, and regulated device software. - Monterail has 150+ experts and has completed 900+ projects globally since 2010. - MAE Group supports medical device, in vitro diagnostic, SaMD, AI-enabled technology, and other digital health companies across regulatory and clinical affairs, quality systems, product development, due diligence, commercialization, financial strategy, and investor readiness. - Companies can learn more about Monterail HealthTech Universe here. - More information about MAE Group is available here.

Between the lines: - The deal reflects a broader shift in HealthTech toward pairing software development with regulatory planning earlier in the process. - Monterail is positioning itself as more than a code shop by packaging development with external domain expertise. - MAE Group gets access to a software-led client base that may need help turning regulated concepts into approvable products.

What's next: - Monterail HealthTech clients can now tap MAE Group support as they move from concept and development into validation, clearance, and commercialization. - The companies said the partnership is intended to help product teams make earlier decisions that are easier to execute later. - HealthTech teams that face FDA, ISO, or CE requirements may use the network to shorten the path from build to launch.